Novartis

Views & Analysis

Collaborating to fight NASH

Eric Hughes, Global Development Unit head at Novartis for Immunology, Hepatology & Dermatology, believes that collaboration is going to be key to finally finding a treatment for non

News

Roche's blockbuster breast cancer drug Herceptin

Sandoz strikes deal with EirGenix for Herceptin biosimilar

Sandoz has struck a deal with Taiwan-based EirGenix to market a late-stage biosimilar of Roche’s breast cancer blockbuster Herceptin.

News

Psoriasis and cardio drugs drive Novartis' Q1 sales

Novartis has begun 2019 at a sprint, upgrading its sales forecasts for the year after strong performances from psoriasis drug Cosentyx and cardiology medicine Entresto.

News

Second death in gene therapy trial prompts investigation

A second death in a study of Novartis’ spinal muscular atrophy gene therapy Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101) – a potential blockbuster for this rare disease – has prompte

News

Novartis files potential blockbuster eye drug with FDA

Novartis has filed its ophthalmology drug brolucizumab with the US regulator, a potentially strong competitor in the tough market for drugs for the degenerative eye condition wet AMD.

Views & Analysis

R&D Roundup: Pharma gets in on the biotech boom

Some good news for the UK industry in turbulent times is always welcome, and several announcement this month showed us why the biotech sector in the country is looking extremely promising g

Collaborating to fight NASH

Sandoz strikes deal with EirGenix for Herceptin biosimilar

Psoriasis and cardio drugs drive Novartis' Q1 sales

Second death in gene therapy trial prompts investigation

Novartis files potential blockbuster eye drug with FDA

R&D Roundup: Pharma gets in on the biotech boom

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Novartis

Editor's Picks